LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

10.24 -1.54

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.24

Max

10.54

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
EPS	-0.828
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+170.03% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	159M 1B
Vorige openingsprijs	11.78
Vorige sluitingsprijs	10.24

Nieuwssentiment

By Acuity

26%

74%

26 / 344 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mei 2026, 21:33 UTC

Winsten

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mei 2026, 21:00 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mei 2026, 20:18 UTC

Winsten

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mei 2026, 23:49 UTC

Marktinformatie

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mei 2026, 23:39 UTC

Marktinformatie

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Global Equities Roundup: Market Talk

27 mei 2026, 23:08 UTC

Marktinformatie

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mei 2026, 22:21 UTC

Marktinformatie

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mei 2026, 21:29 UTC

Populaire aandelen

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mei 2026, 21:08 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mei 2026, 21:02 UTC

Winsten

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mei 2026, 20:59 UTC

Acquisities, Fusies, Overnames

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mei 2026, 20:55 UTC

Winsten

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

27 mei 2026, 20:48 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mei 2026, 20:45 UTC

Winsten

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mei 2026, 20:34 UTC

Acquisities, Fusies, Overnames

Webster Financial Stockholders Approve Sale to Banco Santander

27 mei 2026, 20:32 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mei 2026, 20:30 UTC

Winsten

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mei 2026, 20:30 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mei 2026, 20:22 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:16 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mei 2026, 20:13 UTC

Winsten

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

170.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 170.03%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

26 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.